Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
Ladenburg, Germany, 27 May 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the first patient has been dosed in a Phase I clinical study evaluating HDP-102 for the treatment of non-Hodgkin lymphoma (NHL).
